CVS had what we regard as a good FY20 – showing excellent progress during the first 8 months, highlighting a keen focus on the core business, and then recovering strongly as lockdown conditions eased. This reflects very favourably on the new exec team and the underlying resilience / attractions of the veterinary sector. Pleasingly positive momentum has continued into Q1-21 with LFL sales growth of 3.9% (8.0% comp) and an improved EBITDA margin. In the current climate the veterinary sector has at ....
24 Sep 2020
FY20 finals – prospering under new team & positive FY21 start
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY20 finals – prospering under new team & positive FY21 start
CVS Group plc (CVSG:LON) | 954 104.9 1.2% | Mkt Cap: 684.2m
- Published:
24 Sep 2020 -
Author:
Sahill Shan -
Pages:
3
CVS had what we regard as a good FY20 – showing excellent progress during the first 8 months, highlighting a keen focus on the core business, and then recovering strongly as lockdown conditions eased. This reflects very favourably on the new exec team and the underlying resilience / attractions of the veterinary sector. Pleasingly positive momentum has continued into Q1-21 with LFL sales growth of 3.9% (8.0% comp) and an improved EBITDA margin. In the current climate the veterinary sector has at ....